ArticleBMC cancer2024
Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Clinical value of combinedOncology reviews · 2026Pooled it
- Diagnostic performance of SHOX2 and RASSF1A gene methylation assays in malignant pleural effusion: A systematic review and meta-analysis.Cancer cytopathology · 2025Pooled it
- Value of RASSF1A and SHOX2 methylation detection in intraoperative pleural lavage fluid for potential microdissemination and prognosis evaluation in non-small cell lung cancer.World journal of surgical oncology · 2026Article
- Multimodal modeling based on DNA methylation analysis in bronchoalveolar lavage fluid for early lung cancer detection.Scientific reports · 2026Article
- Molecular Links Between Smoking, COPD, and Lung Cancer: A DNA Methylation Perspective.Cancers · 2026Article
- Transcript-Specific DNA Methylation Alterations of the RASSF1 Locus in Cancer Cells.Genes, chromosomes & cancer · 2026Article
- Small-scale external quality assessment of methylatedClinical chemistry and laboratory medicine · 2026Article
- CMC-WDTK: CpG methylation change prediction by a weight-sharing dual-branch Transformer-Kolmogorov-Arnold network model.BMC genomics · 2026Article
- Epi-liquidomics: redefining cancer diagnostics through epigenetic profiling.Frontiers in epigenetics and epigenomics · 2026Review
- Circulating methylated promoters of HK2 and EGFR as biomarkers in the early detection of cancer.Frontiers in oncology · 2026Article
- Shox2 and Rassf1a DNA methylation: diagnostic utility and association with clinical stage, histological progression and gene mutational landscape in lung adenocarcinoma.Frontiers in oncology · 2026Article
- Using gene methylation detection in bronchoscopic samples combined with morphology-based pathology for lung cancer diagnosis.Frontiers in oncology · 2026Article
- Detection ofMolecular and clinical oncology · 2025Article
- Diagnostic efficacy and subgroup heterogeneity of SHOX2, RASSF1A, Septin9, and HOXA9 methylation in pleural effusion lymphoma.Clinical epigenetics · 2025Article
- Enhancing the precision of auxiliary diagnosis for lung cancer through use ofTranslational lung cancer research · 2025Article
- Catching cancer signals in the blood: Innovative pathways for early esophageal cancer diagnosis.World journal of gastroenterology · 2025Article
- Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.MedComm · 2025Review
- Epigenomic Echoes-Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse.Epigenomes · 2025Review
- Methylation detection in percutaneous lung biopsy preservation fluid: a new strategy to improve lung cancer diagnosis.Frontiers in oncology · 2025Article
- MTPC integration for improved diagnosis of pleural effusion.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Methylation of the promoters of SHOX2 and RASSF1A (LungMe®) exhibits promise as a potential molecular biomarker for diagnosing lung cancer. This study sought to assess the aberrant methylation of SHOX2 and RASSF1A in broncho-exfoliated cells (BEC) and compare it with conventional cytology, histology examination, immunohistochemistry, and serum tumor markers to evaluate the overall diagnostic efficiency for lung cancer. This study recruited 240 patients, including 185 malignant cases and 55 benign cases. In our observation, we noted a slight reduction in the detection sensitivity, however, the ΔCt method exhibited a significant enhancement in specificity when compared to Ct judgment. Consequently, the ΔCt method proves to be a more appropriate approach for interpreting methylation results. The diagnostic sensitivity of cytology and histology was in ranged from 20.0%-35.1% and 42.9%-80%, respectively, while the positive detection rate of LungMe® methylation ranged from 70.0% to 100%. Additionally, our findings indicate a higher prevalence of SHOX2( +) among patients exhibiting medium and high expression of Ki67 (P < 0.01), as opposed to those with low expression of Ki67, but RASSF1A methylation did not show this phenomenon (P = 0.35). Furthermore, CEA, SCCA, and CYFRA21-1 showed positive detection rates of 48.8%, 26.2%, and 55.8%, respectively. Finally, we present a comprehensive lung cancer diagnostic work-up, including LumgMe® methylation. The combined analysis of SHOX2 and RASSF1A methylation serves as a powerful complement and extension to conventional methods, enhancing the accuracy of a lung cancer diagnosis with satisfactory sensitivity and specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.